Zobrazeno 1 - 10
of 226
pro vyhledávání: '"Thomas M. Tzschentke"'
Autor:
Thomas M. Tzschentke, Estelle Watson, Feras Khalil, Claudia Lefeber, Jan Freijer, Mariëlle Eerdekens, Siak Leng Choi
Publikováno v:
Journal of Pain Research. 13:3107-3123
Objective The main aim of this analysis was to characterize the pharmacokinetics (PK) of tapentadol in pediatric patients from birth to
Autor:
Thomas M. Tzschentke, Thomas Christoph, Johanna Korioth, Marta Diaz-delCastillo, Sonny Hermanus Johannes Sliepen, Kris Rutten, Anne-Marie Heegaard
Publikováno v:
Sliepen, S H J, Korioth, J, Christoph, T, Tzschentke, T M, Diaz-delCastillo, M, Heegaard, A-M & Rutten, K 2021, ' The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats : Model validation and pharmacological evaluation ', British Journal of Pharmacology, vol. 178, no. 9, 14899, pp. 1995-2007 . https://doi.org/10.1111/bph.14899
British Journal of Pharmacology
British Journal of Pharmacology
Background and purpose Cancer-induced bone pain remains inadequately controlled, and current standard of care analgesics is accompanied by several side effects. Nociceptin/orphanin FQ peptide (NOP) receptor agonists have demonstrated broad analgesic
Autor:
Petra Bloms-Funke, Michael Schumacher, Song Liu, Diya Su, Jing Li, Philippe Liere, Rainer Rupprecht, Caroline Nothdurfter, Gregor Bahrenberg, Thomas Christoph, Christopher Habermann, Christa Kneip, Wolfgang Schröder, Thomas M. Tzschentke, Derek Saunders
Publikováno v:
European journal of pharmacology. 923
Chronic neuropathic pain (CNP) can result from surgery or traumatic injury, but also from peripheral neuropathies caused by diseases, viral infections, or toxic treatments. Opioids, although very effective for acute pain, do not prevent the developme
Autor:
Thomas M. Tzschentke
Publikováno v:
British Journal of Pharmacology. 178:1973-1994
The treatment of pain, in particular, chronic pain, remains a clinical challenge. This is particularly true for pain associated with severe or rare conditions, such as bone cancer pain, vulvodynia, or complex regional pain syndrome. Over the recent y
Autor:
Stefanie Frosch, Frank Porreca, Wolfgang P. Schröder, Klaus Schiene, Jennifer Y. Xie, Thomas Christoph, Klaus Linz, Thomas M. Tzschentke
Publikováno v:
Behavioural Pharmacology. 30:320-326
The aim of this study was to investigate the efficacy of cebranopadol in two rodent models of visceral pain. Cebranopadol is a first-in-class analgesic with agonist activity at the nociceptin/orphanin FQ opioid peptide receptor and classical µ-, δ-
Autor:
Feras, Khalil, Siak Leng, Choi, Estelle, Watson, Thomas M, Tzschentke, Claudia, Lefeber, Mariëlle, Eerdekens, Jan, Freijer
Publikováno v:
Journal of Pain Research
Objective The main aim of this analysis was to characterize the pharmacokinetics (PK) of tapentadol in pediatric patients from birth to
Autor:
Thomas M. Tzschentke, Kris Rutten
Publikováno v:
Neuropharmacology. 129:100-108
The novel potent analgesic cebranopadol is an agonist at nociceptin/orphanin FQ peptide (NOP) and classical opioid receptors, with the highest in-vitro activity at NOP and mu-opioid peptide (MOP) receptors, and somewhat lower activity at kappa-opioid
Publikováno v:
Addiction Biology. 23:1010-1019
Cebranopadol is a novel potent analgesic agonist at the nociceptin/orphanin FQ peptide (NOP) and classical opioid receptors. As NOP receptor activation has been shown to reduce side effects related to the activation of μ-opioid peptide (MOP) recepto
Publikováno v:
Handbook of experimental pharmacology. 254
Cebranopadol is a novel first-in-class analgesic with highly potent agonistic activity at nociceptin/orphanin FQ peptide (NOP) and opioid receptors. It is highly potent and efficacious across a broad range of preclinical pain models. Its side effect
Autor:
Enrico Polati, Thomas M. Tzschentke, Gabriele Finco, Anthony H. Dickenson, Patrizia Romualdi, Franco Marinangeli, Praveen Anand, Pier Luigi Canonico
The ‘Science of Relief’ event, held in Milan on 10–11 May 2019, was aimed at promoting dialog between different stakeholders among scientific associations, pharma industry, healthcare services and related institutions. The goal was to renew int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65ccda2b7dc7a3a26c6c94624f5e81a
http://hdl.handle.net/11585/723117
http://hdl.handle.net/11585/723117